Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline

磷酸西格列汀一水合物/伊格列净L-脯氨酸盐

Report date: 2022/01/14 13:23:58

Base Information

Drug NameSitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline
Drug Alias NameSitagliptin Phosphate Monohydrate•Ipragliflozin L-Proline磷酸西格列汀一水合物+伊格列净L-脯氨酸盐Sitagliptin Phosphate Monohydrate and Ipragliflozin L-Proline磷酸西格列汀一水合物和伊格列净L-脯氨酸盐西格列汀/伊格列净 +[16] 
ClassificationSmall molecules
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsSodium/glucose cotransporter 2 inhibitors
TargetsDipeptidyl peptidase IVSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2018/03/23
Country/TerritoryJapan
CombinationsYes Ipragliflozin L-ProlineSitagliptin Phosphate Monohydrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAstellas Pharma IncMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma Inc
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10B
Related LinksN/A